Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GARY ALLAN ULANER

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1073730727
CMS profile
792472
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$122,061.57

79 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Progenics Pharmaceuticals, Inc. $94,180.01 63
GE HealthCare $27,536.41 14
Siemens Medical Solutions USA, Inc. $208.19 1
Blue Earth Diagnostics Limited $136.96 1

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GARY ALLAN ULANER

NPI 1073730727 · CMS profile ID 792472

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073730727?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GARY ALLAN ULANER, NPI 1073730727, CMS profile ID 792472. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073730727?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GARY ALLAN ULANER, NPI 1073730727, CMS profile ID 792472. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073730727?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GARY ALLAN ULANER, NPI 1073730727, CMS profile ID 792472, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1073730727?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

79 matching records · $122,061.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 79 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–79 of 79.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Progenics Pharmaceuticals, Inc. $34.0007/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938566255 CMS
Progenics Pharmaceuticals, Inc. $116.1607/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564325 CMS
Progenics Pharmaceuticals, Inc. $123.6007/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564329 CMS
Progenics Pharmaceuticals, Inc. $508.4407/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564359 CMS
Progenics Pharmaceuticals, Inc. $4,440.0007/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564383 CMS
Progenics Pharmaceuticals, Inc. $37.0007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938566257 CMS
Progenics Pharmaceuticals, Inc. $95.9406/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564311 CMS
Progenics Pharmaceuticals, Inc. $121.2406/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564327 CMS
Progenics Pharmaceuticals, Inc. $2,960.0006/29/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564371 CMS
Progenics Pharmaceuticals, Inc. $20.0006/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938566243 CMS
Progenics Pharmaceuticals, Inc. $1,110.0006/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564363 CMS
Progenics Pharmaceuticals, Inc. $174.8906/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564339 CMS
Progenics Pharmaceuticals, Inc. $2,581.7806/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564365 CMS
Progenics Pharmaceuticals, Inc. $115.9606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564323 CMS
Progenics Pharmaceuticals, Inc. $247.9106/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564347 CMS
Progenics Pharmaceuticals, Inc. $2,960.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564369 CMS
Progenics Pharmaceuticals, Inc. $5,180.0005/27/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938566227 CMS
Progenics Pharmaceuticals, Inc. $67.7205/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564305 CMS
Siemens Medical Solutions USA, Inc. $208.1905/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892294349 CMS
Progenics Pharmaceuticals, Inc. $11,100.0004/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938566231 CMS
GE HealthCare $4,928.0004/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430405 CMS
GE HealthCare $1,200.0002/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430295 CMS
Progenics Pharmaceuticals, Inc. $2,590.0002/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564367 CMS
GE HealthCare $2,464.0001/05/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430393 CMS
GE HealthCare $924.0001/05/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430395 CMS
GE HealthCare $60.0001/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430397 CMS
GE HealthCare $679.0001/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430399 CMS
GE HealthCare $286.0001/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430401 CMS
GE HealthCare $72.0001/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953430403 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,775.00 7
PY2020 $4,900.00 2
PY2021 $91,488.92 11
PY2022 $122,061.57 79
PY2023 $161,085.55 106
PY2024 $154,437.34 131
PY2025 $144,638.26 128

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,000.00 1
PY2025 Principal investigator $893,030.62 40
PY2024 Principal investigator $618,760.08 46
PY2023 Principal investigator $111,880.11 9
PY2022 Principal investigator $265,725.95 18
PY2021 Principal investigator $525,695.20 112
PY2020 Recipient $2,139.99 3
PY2019 Recipient $5,354.20 11
PY2019 Principal investigator $164,932.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 LANTHEUS MEDICAL IMAGING, INC. $45,360.00 12/22/2025 Non-covered Recipient Entity
HOAG
EXPANDED ACCESS TREATMENT WITH [LU-177]-PNT2002 FOR ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) No dispute reported 06/30/2026 1245223716
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $77,790.60 10/16/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229225
Recipient SK Life Science, Inc. $5,000.00 09/10/2025 Covered Recipient Physician Ph1a Clinical Study-RPT No dispute reported 06/30/2026 1252275643
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 08/20/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245228857
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 08/11/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245228849
Principal investigator 1 Eli Lilly and Company $15,050.00 07/31/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
[(A)C-225]-PSMA-62 PHASE I/II (C)LINICAL TRIAL TO (C)HARACTERIZE (E)FFICACY, SAFETY, TO(L)ERABILITY, AND DOSIMETRY IN BIOCHEMICALLY RECURRENT AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER (ACCEL) No dispute reported 06/30/2026 1187883406
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 07/22/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245228844
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 07/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245228837
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,500.00 07/03/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190303065
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 07/01/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245228833
Principal investigator 1 Novartis Pharmaceuticals Corporation $145,847.49 06/30/2025 Non-covered Recipient Entity
HOAG HOSPITAL
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190302115
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 06/26/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245231022
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 06/25/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245231016
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 06/03/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245231009
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 05/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230995
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 05/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245231003
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 05/23/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230990
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 05/16/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230984
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 05/13/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230979
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 05/12/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230971
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 04/30/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230966
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,800.00 04/24/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase I/II, open label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast ca No dispute reported 06/30/2026 1190303063
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 04/23/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230931
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 04/21/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230926
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 04/17/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230891
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 03/25/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229630
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,280.53 03/20/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
INVFE No dispute reported 06/30/2026 1245230813
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $1,035.00 03/20/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
INVFE No dispute reported 06/30/2026 1245230913
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 03/17/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229616
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 03/07/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229610
Principal investigator 1 LANTHEUS MEDICAL IMAGING, INC. $200.00 03/01/2025 Non-covered Recipient Entity
HOAG
EXPANDED ACCESS TREATMENT WITH [LU-177]-PNT2002 FOR ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) No dispute reported 06/30/2026 1245223046
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,000.00 02/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in combination with ribocilcib and fulvestrant in subjects participants withER-positive, HER2- negative and GRPR-positive breast cancer, experiencing early relapse from (neo)adj No dispute reported 06/30/2026 1190303061
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 02/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229572
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $5,535.52 02/11/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229564
Principal investigator 1 Novartis Pharmaceuticals Corporation $553.40 01/31/2025 Non-covered Recipient Entity
HOAG HOSPITAL
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in combination with ribocilcib and fulvestrant in subjects participants withER-positive, HER2- negative and GRPR-positive breast cancer, experiencing early relapse from (neo)adj No dispute reported 06/30/2026 1190302109
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $39,788.00 01/29/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229896
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $45,638.23 01/27/2025 Non-covered Recipient Entity
Hoag Memorial Hospital
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy No dispute reported 06/30/2026 1235996867
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $26,303.05 01/23/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
INVFE No dispute reported 06/30/2026 1245229247
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $79,576.00 01/21/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245229872
Principal investigator 1 Novartis Pharmaceuticals Corporation $769.96 01/15/2025 Non-covered Recipient Entity
HOAG HOSPITAL
A Phase I/II, open label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast ca No dispute reported 06/30/2026 1190302111
Principal investigator 1 Novartis Pharmaceuticals Corporation $220,221.40 01/01/2025 Non-covered Recipient Entity
HOAG HOSPITAL
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor No dispute reported 06/30/2026 1190302113